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ABSTRACT 
 
 
 
 
BACKGROUND AND OBJECTIVE 
 
Microalbuminuria has been an established indicator for micro and 
macrovascular pathology in diabetics. But there is growing evidence that 
microalbuminuria may be an important indicator of future chance of 
developing coronary arterial disease. This study was conducted to establish 
a relationship between microalburminuria and Ischemic cardiac Disease in 
non-diabetics. 
 
 
METHODOLOGY 
 
50 randomly selected non-diabetic patients with Ischemic Heart 
Disease who fulfilled the criteria for the study were evaluated for traditional 
risk factors and microalbuminuria in Thanjavur Medical College. 
 
 
RESULTS 
 
Microalbuminuria was detected in 38 (76%) patients with Ischemic 
Heart Disease (p < 0.001). 76.4% patients with infarct pattern on ECG and 
75% patients with ischemia pattern on ECG had microalbuminuria. Majority 
of patients had microalbuminuria levels between 30-50 mg/day (43.2% 
males and 46.2% females). 84.7% of female patients had microalbuminuria 
compared to 73% of the male patients. 79% of hypertensive patients had 
microalbuminuria compared to 71% of normotensive patients. 77.8% of 
smokers with microalbuminuria presented with myocardial infarction 
compared to 54.5% of non-smokers with microalbuminuria. 
 
INTERPRETATION AND CONCLUSION 
 
Our patients with ischemic heart disease had a significantly positive 
association with microalbuminuria. Hence, microalbuminuria can be 
regarded as an additional risk factor for ischemic heart disease. 
 
 
KEY WORDS:  
Ischemic Heart Disease; Cardiovascular disease, Microalbuminuria; 
ECG; Enzyme Linked Immunosorbent Assay; HDL, LDL. 
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INTRODUCTION 
 
 
 
 
Ischemic Heart Disease which has an estimated prevalence of 6-9% 
in the general population in India may become the leading cause of death and 
impairment   in our country by the year 2018. 
 
Since The remarkable research conducted by Framingham trials, many 
cohort based and cross sectional   studies  have  determined  a  group   of   
non dependent risk  factors  for  ischemic heart  disease  among  which  age,   
male gender a previous   familial  history  of young ischemic  heart disease, 
history of cigarette smoke and , history of diabetes  mellitus, systemic 
,hypertension, hypercholesterolemia, hypertriglyceridemia and low incidence 
of good( HDL) cholesterol is taken as  colloquial  risk determinants. 
 
There has been an  interest in increasing  cardiovascular risk 
assessment, as a result of   better knowledge  of the pathophysiology  of  
phenomenon called atherosclerosis and   novel sites  for anti-ischemic 
drug treatment has been identified .This  has stimulated the quest for new 
risk factors. 
 
 
 - 2 - 
 
P
ag
e-
 2
 -
 
One such novel risk factor is microalbuminuria which has emerged 
as an independent and robust risk factor. Microalbuminuria has been 
historically accepted as an indicator for microvascular and macro vascular 
pathology in diabetes mellitus patients. However there has been more 
evidence is pointing out to the fact that microalbuminuria is a significant 
cardiac risk factor even among general population. 
 
The inclusion of microalbuminuria which is an easy to obtain indicator 
along with the classical risk factors may improve risk stratification. 
 
The present study is being conducted  to define the 
micro albuminuria prevalence among non-diabetics patients of Ischemic 
Heart Disease    drawn from lower middle and upper lower class of South 
Indian population admitted to the Thanjavur medical college Thanjavur and 
outpatients attending the outpatient wing of the Department Of Internal 
Medicine and cardiology in Thanjavur medical college, Thanjavur 
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OBJECTIVES 
 
 
 
 
1. To estimate microalbuminuria in non-diabetics having evidence                  
Ischemic cardiac Disease. 
2. To study the relation of micro albuminuria with Ischemic cardiac 
Disease in these subjects. 
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REVIEW OF LITERATURE 
 
 
 
 
Ischemic Heart Disease 
 
Ischemic  refers  to  a  deficiency  of  oxygen  as a result of   
inadequate  blood supply to  the myocardium,  which causes a mismatch 
between oxygen demand and supply . The commonest cause of myocardial 
ischemia is atherosclerotic obstructive disease of epicardial coronary 
arterial system. 
 Atherosclerosis-Pathogenesis 
 
 The term "atherosclerosis" was introduced by Marchand who 
described the relation of fatty sclerosis with vessel wall sclerosis. The 
phenomenon afflicts   large-sized and medium and small vessels and made 
remarkable by discrete intramural   subintimal sclerosis which encroaches on 
lumen of the arteries 
The characteristic lesion of atherosclerosis has three major parts. The 
first of the three is ce l lu l a r  part    which has a majority of smooth  
myoc ytes  fibroblasts   and monocyte macrophage complex. The second 
part is composed of connective tissue with extracellular matrix and lipid 
cellular layer
1
.  
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The third component is the lipid layer in intracellular region which 
accumulates inside macrophages, as a result changing the macrophages to foam 
cells. Lesions of atherosclerosis are due to result of inflammatory reactions, 
subsequent massive cytokine release and multiplication of smooth myocytes, 
connective tissue extracellular matrix synthesis, and accumulation of lipids 
and macrophages and fibroblasts. 
 
The forerunner of Atherogenesis: Endothelial Insult 
The inner  lumen   of  a  ordinary  human   arteriole has  a covering 
made of  endothelium  monolayer  which adheres  to the  endothelial layer  
 
The  cells of endothelium   give   the  vessel  with  a non occlusive  
layer;  platelet   aggregation    retarded  by  presence of   negative      
charge which    endothelium process  and endothelial secretion  of   
inhibitors prostacyclin (PGI) and  also endothelial relaxation  factor known as  
(EDRF-NO). PGI2 along with EDRF-NO, secreted by endothelial cells, 
have relaxation effect on smooth myocytes in tunica media
2
.                       
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 The cell of endothelium produces chemicals that antagonize smooth 
myocyte p r o l i f e r a t i o n  and transfer these cytokines like heparan sulfate 
chondritoin sulfate and EDRF-NO. Lastly,   cells of endothelium protect the 
vessel with a lumen layer to whom macrophages platelets and lymphocytes 
cannot stick. Cells of endothelium which are injured are 
mo r p h o l o g i c a l l y  d i s t i n c t  f ro m o r d i n a r y  endothelium. As distinct 
from normal, they typically does not having same   alignment as blood flow 
direction and they have lesser attachments between cells, causing 
a u g m e n t e d  permeability.   
 
The endothelial cells which are injured also have thrombotic 
tendency when compared with normal cells because of the decreased  
synthesis of EDRF-NO and PGI2. Ischemic endothelium   accelerate 
vascular  smooth  myocyte transfer  and multiplication  by secreting  less 
relaxation factor by releasing  platelet-derived like  growth factor  (PDGF), 
prostacyclins  and  endothelin-2 and endothelin-1. also, ischemic  
endothelium  help   the transfer  of  mo n o c y t e s  by   releasing   monocyte  
chemo attractive   protein-1, , and adherence  using  surface receptors like   
selectins, with  which macrophages will  attach
3
. 
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ROLE IN INFLAMMATION, ENDOTHELIAL DAMAGE AND 
MECHANISM OF LIPIDS 
 
The slowly progressive atherosclerotic p h e n o m e n o n    is 
c o n s p i c u o u s , i n  t h e    early times, b y  disruption i n    endothelium 
f u n c t i o n .  Atherogenesis  is   started  as cellular layer of  endothelium  
over-express adhering  molecules as a  response to turbulence in flow of 
blood   in presence of unfavourable lipid profile .Li  et al showed that  
VCAM-1 expression  on endothelium was an Necessary process  in the 
development  of atherogenesis
4
. 
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DIAGRAM OF NORMAL MUSCULAR ARTERY 
 
 
 
Diagram of Normal Muscular Artery showing outer tunica externa, 
 Middle, media and inner endothelial layer. with internal elastic lamina(IEL)and 
outside connective tissue(CT) 
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  Enhanced  cellular level  adherence  and   co existing  endothelial  
dysfunction  then  results in   for  the aggregation  of inflammatory chemicals,  
cytokines release  and aggregation  of lipid molecules  into the  pathogenic 
plaque. 
 
INFLAMMATION AND CHRONIC ENDOTHELIAL INJURY  
 
 Now it is   generally believed   that   early progress of    pathogenesis o f  
atherosclerosis are controlled, largely, as a result of inflammatory cascade.  
VCAM-1 attachment aggravates transfer  of   subsequently when endothelium is 
injured then secretion   of  monocyte  chemo-attracting  protein  (MCP-1)  by 
polymorphs amplifies  inflammatory cascade with recruitment of additional cells 
, stimulating  polymorphs  in  the layer of  tunica   media,  and  resulting in 
transfer   and   subsequent growth   of smooth  myocytes.  As a  response  to   
signs  created  inside  the  early  plaque of atheroma, monocytes attach  to the 
endothelial layer and subsequently  get transferred  trough the intimal layer  and 
underlying  basement  membrane  by  expressing   enzymes, which include  
regionally  generated matrix metalloproteinase enzymes  (MMP)  which 
destroy  connective   tissue  network
5
 .   
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Transferred monocytes s ec re t e  additional hormones   start travelling 
t h r o u g h  the endothelial surface into tunica media. This phenomenon  is 
still aggravated  by the local   secretion    of   monocyte-colony  stimulating   
factor   (M-CSF),   which   results  macrophage proliferation;  local   
stimulation   of  monocytes  macrophage  leading  to    cytokine- mediated 
progress of  atherosclerosis, and  oxidative damage   of  low-density 
lipoprotein (LDL). 
 
Lots of   inflammatory mediators is known   to affect   the plaque 
development in atherosclerosis. For instance  CD40L  which was elaborated 
inside  the  atheromatous plaque  was   known  to  hike  the  secretion   of  
tissue activating factor  (and  , in all means enhance the possibility   o f   
thrombosis) in atherosclerotic  plaques due to atherosclerosis ; anti- CD40L  
negates evolution of existing  lesions of atherosclerosis  in animal trial 
models
6,7
. 
 
Inflammatory cytokines  elaborated  by myocytes  inside the plaque 
due to atherosclerosis include, but are not confined  to, interleukins (IL)-1ß, 
tumor necrosis factor (TNF) and ß, , MCP-1, IL-18  GM-CSF  and CD-40.  
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The effect of the  cytokines is vast  and include,  cellular matrix 
proliferation, mitogenesis  new     and  ves s e l  g ene r a t i on  and   foa m 
cell  growth at steaks are often the first recognizable  atherosclerotic lesion  
usually  are seen  first in the  surroundings  of vess e l  b ranch sites where  
abnormal hemodynamic  shearing  stresses result in capillary  damage 11. Fat  
streaks are mainly  flat lesions, in  tunica intima  comprising  of smooth 
muscle cells and macrophages and  which contain   lipid  drops s which  give 
the the tissue a foam like  morphology
8
 . 
 
Forerunners of these insults, macroscopic type I,  , lesion, may  be seen  
among   infants as  young   as one years.    Fatty streaks normally show  at  
places   at  where  capillary  insult  has aggravated capillary  leakage enough 
to let in LDL( low- density protein) and other l a r g e  molecules to  
permeate the endothelium. 
 
 Once below the endothelium, LDL (low-density lipoprotein), has a big 
liking for amino sugars and, become sequestrated. LDL (Low-density 
lipoprotein) go through sequence of  changes which cause the production of 
modified variety of LDL (low-density protein.)
9 
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This change  of LDL(low-density lipoprotein) is important for at  three 
causes   is  a  chemical attractant   molecules, with monocyte chemo attractant 
protein(MCP) relased  by injured  capillary cells, transfer  circulating macrophages  
to the subendothelium, where they metamorphose into macrophage.  Monocyte 
transfer is controlled   by aggregation molecules and –capillary l mediated 
leukocyte sticking and chemo attractant molecules. 
 
Also vessel cell adherence to molecule- is expressed in   lumen  of 
damaged endothelium..Also, new LDL (low-density protein) prevent  the exodus  
of  phagocytes from the site.  Last, importantly change of LDL (low-density 
protein) helps tissue to draw huge quantities of fat laden cells 
 
Formation of fibrotic areas 
 
The next step   in the pathogenesis   of a lesion of atherosclerosis   is   
change of the streak to a fibrous plaque like lesion. Fibrous type of  injury  are 
composed of  fibrous  cap  made  of  myocytes  transferred   from  underneath  
endothelium and tunica media. 
Other components of the fibrous cap consist of non functional 
endothelium on Lumen of  the fibrous cap , mo n oc yt e  macrophages, platelets 
and T cell. Undreneath fibrous cap,   fibrous in ju ry  is made o f  lipid cells of 
monocyte ma c r o p h a g e  and myocyte origin. 
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One of the initial incidents causing change of steak to fibrous lesion 
constitutes focal destruction endothelium which covers the lipid steak. 
This  is caused by shear stress exerted  on the non functioning  tissues  from 
derangement  of the vessel tissue wall and from radicals produced in the body  
(free radicals and  products of lipid peroxidation)secreted  by underlying foam 
cells.
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CROSS SECTION OF A ARTERIAL LUMEN DISRUPTED BY 
ARTHEROSCLEROTIC PLAQUE 
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MOLECULAR MEDIATORS OF DEVELOPMENT OF 
ATHEROSCLEROTIC PLAQUE 
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AUTOPSY SPECIMEN OF A LARGE ARTERY DESTROYED BY 
PROGRESSIVE ATHEROSCLEROSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Necrosed blood 
vessel due to 
progressive 
atherosclerosis 
RIM of 
normal 
Vessel 
Lumen 
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ILLUSTRATION SHOWING PROGRESIVE PLAQUE LESION AND 
ADVANCEMENT OF ARTERIAL LUMEN NARROWING 
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FINAL STAGES OF PLAQUE DEVELOPMENT 
 
 One of the  last   step of   pathogenesis   of  the injury   is  the 
metamorphosation  of the fibrous  plaque to advanced plaque,  where a 
thrombotic plaque has developed later due to  atherosclerotic plaque 
ulceration or as a result of  intra plaque haemorrhage. Factors causing plaque 
fracture compose  turbulence and  mechanical shearing  stress, bleeding into 
plaque due  to breakage   of  the small arteries and , increased vessel lumen  
strain  on the fibrous  tip  due  to the existence  of the  pre existing lipid   pool, 
along with secretion  of  extracellular tissue -destroying   enzymes  by 
monocytes which have a presence inside the lesion
10
. 
 
THE ROLE PLAYED BY LIPIDS 
 
The fat and lipid hypothesis which is proposed as a cause of   
atherosclerosis has been drastically modified over the period of last twenty 
years.  Once seen as the initial part of atherosclerosis, it has now been 
accepted that internalisation and aggregation   of lipid starts in response to 
initial alterations in the vessel wall endothelial pathology.   
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Lipid Accumulation is, hitherto, needed for the growth and 
development of the definite plaque.  Lipid deposits are initially started with 
the LDL movement starting from blood stream into blood vessels. Once  it 
reaches inside the  tunica media three  types of fate can occur to  LDL: it can  
return   to  blood stream (a feature of  plaque regression and a  process which 
will  be helped  by some fat lowering measures ), it can be oxidized (with help 
of molecules like free radicals or as a result of direct activity of polymorphs ) 
or it may be endocytosed by monocyte  and then is converted into  foam 
cells.peroxidized LDL can be  notoriously atherosclerotic and has affinity for 
fibroblasts and- macrophages.  
 
Monocyte system Monocytes Macrophages attach to intimal LDL 
through group of new receptors also known by the name scavenger receptor, 
identifying LDL after the molecule is per oxidized. Intake of peroxidized   
LDL   makes   the   monocytes less active, hence promotes the aggregation of 
the fat-filled cells of the tunica intima. 
 
The lipid laden foam cells regain the   activeness and release   wide 
variety of chemokines and other   inflammatory cells.  
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Results of the aggregation include transfer with aggregation of smooth 
myocytes  to elaborate more locally acting chemokines), further  LDL  
destruction and peroxidation,  deployment and transfer of extra macrophages 
and  monocyte/lipid laden cells with further  destruction and damage and  
impairment of endothelial  cell function. 
 
Some plaques   proliferate inside  the plaque, probably in response to 
local angiogenic cascade The potential significance  of phenomenon called  
angiogenesis in  pathophysiology of atherosclerosis is demonstrated  in 
experiments  that  which  show  anti angiogenic treatment decreased 
atheromatous lesion progress in a  placebo control trial  in atherosclerosis 
pathology  prone mice 
 
Two types of plaque destruction are seen: superfluous injury& deep 
injury. The first type injury results in patchy regions of focal endothelial 
destruction which grow leading to the Development of mural and even 
adhesive thrombus. Plaques that are filled  with  collagen  tissue,   delineated  
by  huge  amount   of  lipid-laden macrophage monocytes which   tend  to lead 
to superficial insults
11
 .  
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Deep vessel insult is conspicuous by a split or shear which extends from 
lumen of   plaque   into substance of the plaque. This type of insult, occur in 
plaque which has a large fat-rich pool, exposing blood and its components to 
the highly thrombotic contents that makes up the plaque. 
 
Thrombus  activation can affect the  course of the phenomenon called 
atherogenesis; in presence of  an emergency  like  myocardial infarction and 
unstable  angina  caused due to release of chemokines like  von Wile brand  
tissue factor-controlled  platelet aggregation adhesion  .and activation 
 
PREVENTION AND EPIDEMIOLOGY OF ATHEROSCLEROSIS 
Atherosclerosis which is a multifactorial entity whose age of start and 
progress are greatly influenced by a plethora of inborn and acquired risk. 
Since the exemplerary work of the Framingham trials, various prospective 
trials  and clinical and non clinical  studies have identified a group  of risk 
factors for  myocardial infarction, and  peripheral vascular disease, and  
stroke  among which the pre-existence of atherosclerotic vascular disease,  
age,  male  sex  similar  history of  premature  atherosclerotic disease in 
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family ,history of smoking, history of diabetes mellitus, hypertension, history 
of dyslipidemia and  low serum  HDL  cholesterol  have been considered as 
colloquial risk determinants
12
. 
 
In recent past results of two randomized control trials involving of 
more than 600000 candidates  in 16 assessment  trials  and four observational 
trials  have proved that  that 70-80% of patients who later had   significant 
ischemic heart pathology  had at least two of four colloquial  risk   
determinants viz dyslipidemia  (blood  cholesterol >250mg /dl /6.22  mmol/l),  
hypertension  (systolic BP  >146 mm  Hg  and/or diastolic BP >94 mm Hg),  
prevalence of diabetes mellitus and history of  smoking. A single risk 
determinant doesn’t carry much weight but a combination of various risk 
factors carry great importance .hence at this point of time the best way to 
asses the risk is to tabulate the determinants in a an algorithm and then 
statistically asses the risk.  
 
 This method has been taken as the best means to asses the whether a 
person will have an ischemic insult to heart within next ten years many 
algorithms has been developed worldwide but best of them are 
FRAMINGHAM GUIDELINES from USA and Germanys   PROCAM   
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trial
14, 15
.   Various current guidelines have made their recommendations first 
starting lipid lowering therapy and BP lowering therapy depending on global 
risk stratification. 
 
Even with best screening algorithms the chance of detecting people 
with low risk of cardiac illness will require cost intensive screening of big 
populations. But in such situations presence of high false positive results lead 
to wrong treatment given to general public. 
 
The growing  in te res t  worldwide i n  improving cardiovascular risk 
assessment and preventing cardiac morbidity and mortality resulting from a 
better knowledge of  natural course of the  of atheroma s and identifying  of 
novel targets  for anti-atherogenesis drug  had resulted in search for novel 
risks.  Many cross sectional cohort and randomized control studies have 
shown existence of several biomarkers with ischemic heart disease. 
Unfortunately most of the markers were not reproducible in further studies 
and most of them were inter related to classical risk factors but nowadays 
some of these markers appear to be genuinely independent and not 
dependent on classic risk factors. 
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Here there is an active debate ranging about their utility in routine risk 
assessment. Of all these most important are Lp (a), homocysteine micro 
albuminuria fibrinogen and CRP
13
 
 
 
 
LIPROTEIN (A) 
 
A consensus about the standardisation has only been recently 
recognized and hence it use as a marker is still in rudimentary stages. Now a 
days most labs take a standard of 30 ng/ml above which risk of ischemic heart 
disease is to be suspected in spite its high genetic predisposition of blood Lp 
(a) levels. It doesn’t have much intraindividual changes but, renal impairment 
and overt excretion of protein  
 
 
It will result in high serum LP (a). In other words serum Lp (a) level 
doesn’t have much significance but prevalence of variability of its protein 
ingredient, apolipoprotein (a), ultimately determine susceptibility of a person 
towards cardiac illness 
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C-REACTIVE PROTEIN 
CRP levels more than 1 mg/l has been associated with mild risk while a 
level above 3mg/l has been associated with significant risk of ischemic heart 
disease. But CRP LEVELS is affected by BOTH types of   inflammation and it 
is not unusual to find levels of more than 10 mg/ml and still patient in good 
shape 
16
. 
 
FIBRINOGEN 
Fibrinogen assays like CRP AND LP (a) have not been    standardized 
internationally. Citrate is needed in the anayzlate which makes cumbersome 
specimen. Also fibrinogen is an acute phase marker; hence it is virtually 
useless in patients having acute and chronic inflammation. 
 
MICROALBUMINURIA DEFINITION OF MICROALBUMINURIA 
 A broad definition for micro albuminuria was adopted in 1995 
which determined it as abnormal in individuals with impaired glycemic 
metabolism   as an abnormal elimination of albumin falling within the range 
of 25-200 microgram/minute or instead taken as 30-300 milligram/day.36 this 
definition still holds good and may be applied for all patients without 
regarding their co morbid conditions
17
. 
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It was following research of  Viberti and colleagues that   the word MA 
has come into existence but still the so defined Levels of microalbuminuria  is 
an artificial group which is composed of continuum results
14, 18
. 
 All the public screening  and survey data has shown the fact that 
microalbuminuria has been related to an augmented risk for generalized 
mortality and morbidity,  strokes(cerebrovascular  disease, ) and,  probably 
implicated in the pathogenesis of,  peripheral  arterial  mortality causing 
diseases 
As a result of 7 year follow up study of apparently healthy  subjects  
(without co morbid factors   like diabetes, hypertension  and CVD),  the 
chance of with the level of UAE not developing cardiac pathology  showed 
a linear relation  in the whole study population and  also in the cohort of  
subjects  having  albumin excretion just  below the  minimum cut off for 
microalbuminuria. 
In the Heart Outcome and Prevention Evaluation (HOPE) study, UAE 
urinary albumin excretion) did predict chance of mortality in subjects With 
more than  55 yr  age with CAD and diabetes with minimum one more 
cardiovascular risk determinant).the causes of death due to all causes was 9.5% 
in subjects not having microalbuminuria  viz  18.%in the group  having  
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microalbuminuria  ( [RR] 3.11% 95% confidence level [CI]  2.85to 3.39). A 
direct association was observed with the microalbuminuria and cardiac 
pathologies, which extend beneath  the normal threshold of microalbuminuria  
The incidence of microalbuminuria does seem to foretell all round 
reasons of death in the public populace.  the amazing fact  was first depicted 
by  Prevention of the  Reno Vascular  End  stages   Diseases  (PREVEND)  
trial ,  where  natives of city of  Groningen, Nederland, in the age group  29 to 
77 yr were given a verbal question bank  and provided  bottle  to catch  the 
first -morning urine clean catch  sample for  assessment of  urinary 
albuminary excretion(UAE)
19
. 
A gross number o f  40 ,458 candidates were prospectively assessed fo r  
a time period of 2 .8  yr were made the part of study And detailed analysis of 
death by measurement of base urinary albuminary excretion (UAE.) 
 There seem to be a valid positive association of  urinary albuminary 
excretion( UAE) and all reasons of death due to cardiac and non cardiac illness 
Microalbuminuria  does seem to have an association with various 
cardiovascular  abnormalities, which include  left ventricle chamber 
(LV) dysfunction and hyperplasia holter  monitoring defects, and 
existence coronary artery Heart Disease (CAHD).  
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The Strong Heart TRIAL did show a relation of microalbuminuria and 
abnormal echocardiographic parameters of both RV and LV systolic and 
diastolic work assessment in  a g roup  of  1578 indigenous Americans with 
impaired glycemic tolerance.
20 
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Table  1:  Clinical  studies  reporting  the   risks  associated  with  a  positive 
microalbuminuria result 
(A) Prospective studies 
 
 
No Study Microalbuminuria 
Definition 
Population Risk Associated with a 
Positive Microalbuminuri 
Result (95% CI) 
1 Prospective 
studies 
HOPE  
ACR >=2 mg/mmol in a 
first morning spot urine 
sample 
Subjects at high 
cardiovascular risk 
>=55 yr with CVD or 
with diabetes +>=1 
CVD risk factor; n = 
9043) 
All-cause mortality: RR 
2.09 (1.84 to 2.38) 
2 PREVEND UAE 20 to 200 mg/L in 
an early morning spot 
urine sample 
Residents of 
Gronngen, the 
Nederland, 28 to 
75 yr 
(n = 40,548) 
Cardiovascular death: 
RR 
1.29 (1.18 to 1.40) Non 
cardiovascular death: 
RR 1.12 
(1.04 to 1.21) 
3 PREVEND UAE 30 to 300 mg in a 
24-h urine Sample 
Residents of 
Groningen, the 
Nederland, 28 to 75 yr 
(n = 7330) 
All-cause mortality: HR 
3.3 (1.5 to 7.1) for 
patients with ST-T 
segment changes 
microalbuminuria versus 
0.9 (0.4 to 1.9) for ST-T 
segment changes alone 
Cardiovascular death: 
HR 10.4 (2.5 to 43.6) for 
patients with ST-T 
segment changes _ 
microalbuminuria versus 
2.7(0.6 to 12.3) for ST-T 
segment changes alone 
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(B) Cross-sectional studies 
 
No 
 
Study 
Microalbuminuria 
Definition 
 
Population Risk Associated with a 
Positive Microalbuminuri 
Result (95% CI) 
4 Hoorn Study ACR >= mg/mmol in a 
first morning spot urine sample 
Population-based: 
White individuals, 50 to 75 
yr (n = 631) 
Cardiovascular death: RR 
3.22 (1.28 to 8.06) All- cause 
mortality: RR 1.70 (0.86 to 
3.34) All-cause mortality in 
patients with hypertension: RR 
2.87 (1.22 to 6.33) 
5 HUNT ACR >=76 mg/mmol 
(_60th percentile) in a first-
morning spot urine sample 
Nondiabetic, 
nonhypertensive residents of 
Nord- røndelag,Norway, 
>=20 yr (n =2089) 
All-cause mortality: RR 
2.3 (1.0 to 5.4) 
6 EPIC-Norfolk ACR 2.5 to 25 mg/mmol 
in a random spot urine sample 
Residents of Norfolk, 
UK, 40 to 79 yr (n = 
20,911) 
All-cause mortality: HR 
1.48 (1.20 to 
1.79)Cardiovascular death: HR 
2.03 (1.55 to 
2.67) Fatal stroke: HR 
1.58 (1.10 to 
3.0)Coronary heart disease 
death: HR 2.01 (1.40 to 2.90 
7 EPIC-Norfolk ACR 2.5 to 25 mg/mmol 
in a random spot urine sample 
Residents of Norfolk, 
UK, 40 to 79 yr (n 
_=23,630) 
Stroke: HR 1.49 (1.13 to 
2.14) 
8 Third 
Copenhagen City 
Heart Study 
UAE >.8 _g/min (> 3
rd
 
quartile) in a timed overnight 
urine sample 
Residents of 
Copenhagen, Denmark, 30 
to 70 yr, without coronary 
heart disease 
All-cause mortality: RR 
1.9 (1.5 to 2.4) Coronary heart 
disease: RR 2.0 (1.4 to 3.0) 
9 Danish 
MONICA 
ACR >0.65 mg/mmol 
(>90thpercentile) in a first-
morning spot urine sample 
Population-based: 
Individuals without Ischemic 
Heart Disease, renal disease, 
urinary tractinfection, or 
diabetes (n =2085)) 
Ischemic Heart Disease: 
RR 2.3 (1.3 to 3.9) 
10 Shibata Study Positive albumin dipstick 
test 
Residents of Shibata, 
Japan, >40 yr (n = 
2651) 
Stroke: RR in men 2.5 
(1.1 to 5.7 
11 Portland 
Study 
UAE 20 to 200 mg/L in a 
first morning spot urine 
sample) 
Older residents of 
Portland,oregon,with 
previous stroke or 
transient ischemic 
attack (n =121) 
Recurrent stroke: HR 4.9 
(1.4 to 17.6) 
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No 
 
 
Study 
 
Microalbuminuria 
Definition 
 
Population Risk Associated with a 
Positive Microalbuminuri 
Result (95% CI) 
12 Slowik et al. UAE 30 to 300 mg in a 
24-h urine Sample 
Patients admitted 
within 24 h of 
A first ischeic stroke 
(n = 60) 
Mortality: OR 6.0 (1.3 to 
27.7) 
13 Cross-sectional 
studies 
Zander et al. 
UAE 20 to 200 mg/L in 
an early morning spot urine 
sample 
Patients with type 2 
diabetes 
(n =1060) 
PAD: OR 2.1 (1.4 to 3.2) 
14 PREVEND UAE 30 to 300 mg in a 
24-h urine sample 
Nondiabetic residents 
of Groningen, (, 28 to 75 
yr(n = 7579) 
Electrocardiographic 
abnormalities: Infarct patterns: 
OR 1.61 (1.12 to 
2.32) 
Major ischemia: OR 1.43 (1.08 
to 1.91) 
Minor ischemia: OR 1.32 (1.03 
to 1.68) 
15 PREVEND UAE 30 to 300 mg in a 
24-h urine sample 
Nondiabeticresidents 
of Groningen,the 
Netherlands,  28  to  75 yr 
(n = 6669) 
PAD:  OR  0.98  (0.68  to 
1.41) in multivariate 
analysis 
16 Earle et al. UAE 20 to 200 _g/min in 
a timed overnight urine sample 
Patients   with   type   1 
diabetes and without CVD 
Silent myocardial 
ischemia: OR 6.3 (1.2 to 
37.8) 
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Most of the albumin which has been filtered is reabsorbed by the proximal 
tubule via low capacity phagocytic process. About 15-28mg/24h of albumin 
which will be present in urine.  if we calculate that about  8 gramme of albumin is 
processed every day, a unit hike  in generalized vascular permissiveness of 
system  the  in  response to an insult or  a injury  would cause   an extra  75 mg of 
albumin which gets through the filters .already corrective mechanisms for tubular 
reabsorption of albumin have been exhausted completely so this will cause, 
urinary albumin excretion hike  from a range  of 30 to around  120 mg in 24 
hours.
21 
Nephronal permissiveness to albumin is related to not only charge 
selectivity present on endothelium but also selectivity regarding the size. The 
nephronal membranes will have a negative charge by its constituent 
glycoproteins plays which help in preventing in loss of anions .it has also been 
noted that there is a decrease in nephronal charge selectivity in subjects with 
microalbuminuria regardless whether they are diabetic or non diabetic. 
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ILLUSTRATION OF THE VICIOUS CYCLE BY WHICH 
MICROALBUMINURIA CAUSE ENDOTHELIAL INJURY AND 
ENDORGAN DAMAGE  (MOLECULAR PATHWAY) 
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Also changes in the amount of plasma processed by the nephrons due to 
variations in glomerular blood pressure regulation will cause relatively huge 
variations in amount of albumin excretion. 
Microalbuminuria may be a indicator o f  generalized vascular 
pathology, with arterial endothelial dysfunction being involved in the 
pathogenesis of atherothrombotic vascular disease. 
At present there is no consensus of opinion regarding exactly how 
MA causes or accentuates atheroma formation and subsequent degeneration. 
but at present it is widely assumed  that mechanisms of vessel toxicity  
related  with MA are distinct from those subjects  with or  without diabetes 
and who have co existing  hypertension.
22 
In patients   with  MA  who  are not suffering from diabetes,  the  
endothelial malfunction and  changes  in the cellular involvement  will lead to  
to  a hike  in vascular leakage and as result accentuates the degenerative process. 
Of atherosclerosis abnormal endothelial leakage causes lipid influx into the 
tunica media and intima of vessel causing degenerative changes at present it is 
assumed that MA won’t be directly implicated in the pathogenesis of 
nondiabetic vascular or renal disease solely due to hypertension. This ambiguity 
will help us relate to association that the albumin moiety doesn’t have a glycated 
form 
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Table 2: Pathologic steps in relation with MA 
Local STEPS  
 
1. Elevated intraglomerular capillary oncotic pressure 
 
 
2. Accentuated transport of albumin mediated through pores in glomerulus 
 
Systemic steps 
 
1.  Inflammatory mediator’s activation cascade 
 
2. Elevated intracapillary albumin leakage  
 
 
3. Endothelium malfunction of the vessels 
 
 
Table 3: Factors influencing the MA development. 
 
1. High quetlet index(BMI) 
 
2. Elevated bp(systolic and diastolic) 
 
3. Dyslipidemia 
 
4.  Resistance to insulin (syndrome X) 
 
5. Cigarette and beedi abuse 
 
6. Exaggerated sensitivity to salt 
 
7. Old age  
 
8. Endothelium mal function 
 
 
 
 
 36 
 
P
ag
e3
6
 
 The endothelium synthesis proteins   of the cellular matrix   and  help  
synthesis of several important cardiac and renal  proteins. An mismatch between 
normal endothelial and absence of homeostasis between vasodilatation and anti 
thrombosis i s  a main reason causing atheromas. hence it has been assumed that 
defective permeability of endothelium  may be cause of the   of  MA  in  the  
general  population, in  the patients with   s y s t e m i c  hypertension,  and  
patients   with  diabetes.  Even though    malfunction of endothelium is not a 
distinct process, several analysis and observations suggest that endothelial 
dysfunction may show a common pathogenesis for both micro and macro vascular 
morbidities
23
. 
  
 Endothelial dysfunction will have a key role in (non- diabetic causes of 
atherosclerosis.  Altered permiss iveness  of  t h e  intima permits   lipoproteins 
(oxidized LDL) to enter in to  the large blood vessels and help in the growth of  
plaques.   the accentuation   in  vascular leakage   accompanied  with decreased 
response of  beta-receptor  results in impaired insulin action by preventing  
insulin-helped skeletal myocyte vasodilation which interferes with  insulin 
associated  glucose re uptake. 
 
 
 37 
 
P
ag
e3
7
 
 
Micro albuminaria  is related with  biochemical indices of endothelial 
malfunction like elevated von Willebrand factor and accentuated platelet 
aggregation. 
It was observed that in both non-diabetic subjects with essential 
hypertension and diabetic patients participants having microalbuminuria had 
elevated plasma levels of vWF antigen than patients having normal albumin 
excretion. 
Other biochemical indices of endothelial malfunctioning include increase 
in the Serum levels    of  angiotensin  II,  PA  )  and thrombotic profile  
consisting of plasminogen  activator  and  inhibitor–1  (PAI-1)  and  new 
molecule called endothelin
24
.  
So it can be assumed that  endothelial malfunction play a important 
part in) glomerulosclerosis in non diabetics, MA assisted insulin sensitivity and 
development of atherosclerosis. 
 
MA is  an early   indicator  of  target   end organ  damage related  with 
CVD but has been related  with accentuated cardiac mortality and morbidity 
in non diabetics Aggerwall and co workers showed a significantly higher 
occurrence of ischemic heart disease CVA, and peripheral diseases in arteries  
in patients  with MA 
 38 
 
P
ag
e3
8
 
MULTIPLE EFFECTS OF MICROALBUMINURIA ON  
VARIOUS SYSTEMS 
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MA has a direct relation with severity of morbidity. The conditions which 
follow this dictum are reperfusion and ischemia. MA has also seen in the setting 
of an acute infarction of myocardium and peripheral arterial disease and has 
direct relation with severity of the infarct or severity of claudication. The STENO 
theory forwarded by Deckard and colleagues.  Albumin leak into the urine 
reflects generalized vessel damage. Hence the nephron is the assumed as key part 
of the vessel system
25
. 
In lieu of the theories of endothelial mal function and chronic persistent 
inflammation are possible ways to arrive at a link of   micro albuminuria and 
ischemic heart disease.  But there are many discrepancies in the texts.  
Even though it’s right that persistent inflammation can be cause and 
a endothelial malfunction, some trials used markers such as, TNF-α IL-1, IL-
6, which suggest that persistent inflammation is associated with 
p r o g r e s s i o n  of microalbuminuria and which is related with an 
 increased chance  for atherosclerotic vessel damage.    but another group 
of    trials show   that  though  microalbuminuria, endothelial   dysfunction,  
and persistent and   low-grade  inflammation  are  having links,  they  are 
also considered as  independent risk factor cardiac mortality
26
. 
Many cross-sectional case control and cohort and  prospective trials 
showed  that microalbuminuria was having relation with many cardiac  risk 
determinants like age,  history of hypertension, history of diabetes, history 
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of  smoking,  prevalence of  obesity, and abnormal lipid profile  these   
explain,   only  a   very  small  portion of  the  relation of micro albuminuria  
with  atheromatous  events. 
Hence with regard  to endothelium  function  and  inflammation there is 
a chance   t h a t  t h i s  will cause  both microalbuminuria  along with ischemic 
heart disease  yet  a another hypothesis  is that  most of the people having 
varying degree of  vessel derangement within normal range and, hence, 
eliminate a varying quantity of micro albumin. This existing vagarisms  of 
the vessel wall  state can be assessed  by urine micro albumin elimination  
which may be related  with chance of  further end   organ  damage.   This 
explains why micro albuminuria is   good predictive marker of both 
ischemic heart  disease and recent-onset systemic hypertension and 
glycemic impairment.  In this  scenario, then it is advisable  to mark these 
susceptible  to asses  early primary prevention in such a scenario, the renal 
system may serve as an approximate measure of  BP ; that is, target BP  where 
normal urinary albumin excretion is present also, intensive.  
Sugar control   and aggressive control   of LDL if coexisting   with 
stabilization of albumin elimination will be a suitable marker of prognosis as 
far as therapy is concerned
27
. 
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Yudkkin et al  were did a cohort study  of MA(24-hour daytime  UAE 
> 30 microgram/min) with assessment of cardiovascular and peripheral vessel 
disease risk in a cohort of 189 patients (58 diabetic or impaired  glycemic 
tolerance )  in the Islllington Diabetes trials 
In the cohort study , Yudkkin et al  demonstrated  a independent 
relation  of  MA  with   prevalence of  all-cause morbidity and mortality  [7/19  
(34.12%)]  vs. [3/148  (2.03%)]normal albumin excreting  individuals in 
167patients after a median  3.7years follow-up 
33
. 
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Table 4: List comparing h o r i z o n t a l  (C) and cohort (P) trials 
showing M i c r o a l b u m i n u r i a  in non diabetics a n d  urinary albumin 
excretion used as predictor of cardiac pathology 
 
No Author/ref. year No 
patient
s 
Design End-point Population 
 
 
 
1 
 
 
 
Yudkin  
 
 
 
1988 
 
 
 
187 
 
 
 
P 
ECG changes 
 
Incidence of MI 
PVD and angina 
Diabetics,IGT,NON 
diabetic patients 
2 Haffner  1990 316 P MI Normal subjects 
3 Damsgaard 1999 217 C Deaths in total Normal subjects 
 
4 
Winocour 
 
1999 
 
448 
 
p 
Ecg changes both patients 
5 Damsgaard 1992 218 C  ECG abnormality Normal patients 
6 Damsgaard 1998 217 C  DEATHS due to 
cvs pathology 
Normal patients 
 
7 
 
Gould 
2001 
 
957 
 
P 
MI, PVD Normal patients 
 
8 
 
Howard 
 
2002 
 
4569 
 
P 
Definite MI 
 
Diabetic Americans 
 
9 
 
Kuusisto 
 
1997 
 
1079 
 
C 
Cahd fatal and non 
fatal 
Normal patients 
 
10 
Gorgels  
1994 
 
232 
 
C 
 
MI and angina 
 
Both groups 
 
11 
 
Agerwall 
 
1995 
 
119 
 
C 
 
Carotid 
atheroscerosis 
94 essential hypertensives 
NIDDM  
 
12 
Bigazzi  
 
1998 
 
92 
 
P 
 
MI 
normotensives 
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No Author/ref. Date N Design End-point Population 
 
13 
 
Ljungman 
 
1996 
 
120 
 
P 
PVD HTNS and normal people 
14 Jensen  1997 2613 P MI Both groups 
15 Jensen  2003 1254 P Previous CAHD HYPERTENSIVES 
16 Mykkanen 
 
2004 
 
1441 
 
C 
Subclinical carotid 
atherosclerosis 
991 non-diabetic, 450 
diabetic 
17 Pontremoli  
 
2002 
 
53 
 
C 
Subclinical carotid 
atherosclerosis 
Hyper- and normotensive 
subjects 
18 Fabsitz 
 
2001 
 
4276 
 
C 
Ankle/brachial 
index < 0.9 
 
American diabetics 
19 
 
Jager  
 
1999 
 
631 
 
P 
All CVS mortality Both groups 
 
20 
 
Beamer  
 
1999 
 
121 
 
P 
 
Stroke, MI, 
vascular death 
Diabetic and normal 
patients 
21 Diercks  2000 7579 P Holter changes Normal patients 
22 
 
Gerstein  
 
2000 
 
5708 
 
C 
 
Peripheral 
vascular disease 
Non-diabetic with 
cardiovascul
ar disease 
23 Jensen 2001 207 C MI CAHD PVD 
Uncomplicated 
hypertensive 
subjects 
24 Pedrinelli 2000 136 C Carotid ischemia 
Uncomplicated 
hypertensive 
men 
25 Roest 2001 1 118 P 
 
MI,angina 
Postmenopausal women 
26 Gerstein 2001 5 545 P 
All CAHD 
mortality 
Non-diabetic with 
cardiovascular disease. 
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AN ALGORITHM FOR ASSESSMENT OF MICROALBUMINURIA IN 
HYPERTENSION AND DIABETES 
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The recently finished PREVEND trial where MA (30–300 mg/24 h) was 
firm and independent association with electrocardiographic prevalence of 
either infarction or existence of ischemia in 7 5 8 9  ind iv idua l s  with no 
history of diabetes.    The HOPE t r i a l  also demonstrated   that M A  (MA: 
ACR_3mg/mmol) has very crucial    and independent role as p red ic to r  
among 5709 individuals not having diabetes with well established vascular 
pathology
29
. 
In  the  American  Indians who were non diabetic  in the  Strong  
Heart  trials,  the existence of  ischemic   cardiac disease, C V A ,  
peripheral arterial  disease was related  with micro albuminuria prevalence 
(ACR - 32 and 320 mg/g) regardless  of age, BP, glycemic impairment  
dyslipidemia along with  serum  fibrinogen
39
  
In 1079 nondiabetic Finnish individuals from the Kuopo community 
who were prospectively  followed up 3.5 years, the occurrence of  death due 
to cardiac and coronary  pathologies  increased by twice in  view of ACR > 
3.32 mg/mmol. When adjustment was done for various confounding variables, 
like hypertension, the relation was weakened
30, 31
. 
Damsgaard et al. by their pioneering research that microalbuminuria is 
associated with three times higher mortality. 
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In patients with normal sugar levels where a lbuminur i a  was equal to or 
we l l  a h e a d  o f  me a n  r a n g e  (>7.62 micro g /min ;) in comparison with 
people below (43/109 vs. 9/108). 
The relation between microalbuminuria and ischemic heart disease may not 
be just accidental but the two may be bound by a common pathophysiologic 
process.  Although many deranged physiology   of t h e  v e s s e l  wall   predispose 
to microalbuminuria and  ischemic heart   disease     
The endothelial malfunction  is  taken as causative factor  of  
atherosclerosis  and  is believed  to  have  an significant role in prognosis of 
atherosclerotic process .hence, a relation of microalbuminuria with gross   
endothelial malfunction, which if is there , will  explain why microalbuminuria 
is good marker of ischemic heart  disease. also, microalbuminuria in both type 
of diabetes usually is associated with  endothelial  malfunction a n d , and 
EDRF NO  synthesis and its availability and acceptability, as calculated  by 
blood  level of chemokine agents  such as, tissue- plasminogen type  activator, 
vascular cell  and soluble variety of  E- selectin and by endothelial-dependent 
dilatation of blood vessels  as a  response to augmentation in flow or increase in 
cholinergic chemicals.,, hence endothelium mal function in Patients having 
diabetes with  micro albuminuria,  is exhaustive. 
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 A   small  survey  f o u n d  an altered   endothelial  vascular  response  
which was related with  microalbuminuria .it was noted in the brachial renal 
arteries and  other abdominal arteries  but not much awareness is there if of any of 
the trials which have been carried out, for instance, in coronary vessel 
circulation.
32 
There are very less  trial on the amount  of endothelium  mal function in  
patients who are non diabetic  with micro albuminuria, but existence of  
endothelium mal function, in diabetes, has been theorized  as  to control  the  
hemostasis regulation , and  fibrinolysis system control,  polymorph adhesion,   
EDRF NO  Production s  and accessibility.   
For   instance,  one  current,  big, population  survey  of 647 subjects 
(median age 69 years; 249 with  normal blood sugar, 139 with impaired  
g lycemic metabolism, and 261 with  h i s to ry o f  type 2 diabetes)  
demonstrated  that  endothelial NO production, as calculated from ultrasonically 
calculated brachial artery   endothelial  flow -dependent, flow-determined 
dilation, was deranged in individuals with diabetes.
34
   
These data stress  the fact that altered endothelial EDR F NO production 
Has  a role in the relation of microalbuminuria with all type of  cardiovascular 
morbidity and mortality risk regardless whether glycemic impairment  is present 
or not . also, several trials have stressed that endothelial  mal function  predates   
and  foretells   the start  of  microalbuminuria  patients  with  and without 
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diabetes. 
 Hence it is   is tempting to tell   that endothelial malfunction in 
microalbuminuria shows why micro albuminuria has always been. a consistent  
and fairly accurate marker of increased probability of risk  for atherothrombosis. In the 
past, glomerular permissivity   was postulated to depend mostly on basement 
membrane of the glomerulus c o n s t i t u t i o n  and slit diaphragm morphology. 
current studies have shown,  a   significant   active  role  of  the glomerular 
endothelium in assessing penetration to albumin .specially, the negative charged 
glycocalyx that covers the  endothelium fenestrations is the most  significant 
parameter  for assess ing glomerular  permeability and  ion selectivity.
35 
Alterations  in the endothelial layer of outer glycocalix will  have a 
contribution to Micro albuminuria but  this  has been  blamed in the 
pathophysiology causing atherosclerosis,  which  gives   a  potential  dangerous 
liaison   between  albuminuria  and probability  cardiovascular morbidity and 
mortality .  In this context  recent studies  probable common pathway  for  
increased    albumin  leakage from glomerulus  vascular disease has shown new 
data  on the belief   that micro albuminuria shows  systemic flow dependent 
intravascular  loss of   albumin,  resulting  in preponderance    to  increased 
presence   of atheromatous  lipoprotein  plaque  molecules into    arterial  tunica 
media—  Steno theory36
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Athero thrombosis at present is  cons idered  as a phenomenon  in 
which endothelial malfunction and, persistent inflammation are significant 
initial events. also, long standing low-grade degradation result in endothelial 
mal function, and the both of them  are strongly associated long standing  
persistent vessel inflammation which may be gauged  by measuring C-reactive 
protein levels in both  diabetic and non diabetic  patients microalbuminuria  has 
been related  with an predisposition to cardiac  risk, which is  independent when 
as   compared to known risk factors.  
Also microalbuminuria can be a future useful tool for improved and 
advanced cardiac risk assessment. Its is certain that  in the co existence  of 
microalbuminuria, strict monitoring  of cardiovascular  risk determinants  is 
necessary the exact mechanism with which  microalbuminuria is related  to 
cardiac pathology  risk is not known. I t  i s  n o t   c l e a r  i f  at present     
microalbuminuria results in atheroma or the other way around .one postulation is 
that common risk determinant may be the real culprit for causing  the relation of  
microalbuminuria and cardiac illness and  disease, but there is no clear evidence 
regarding the same  The relation  of  microalbuminuria w i t h  cardiac illness 
may be  associated  by a common pathology, like  endothelial mal function and 
chronic, persistent  inflammation. Many more trials are definitely needed to 
increase our knowledge in this field
37
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MONITORING, SCREENING DIAGANOSIS AND TREATMENT 
ALBUMINURIA 
 
BASIC PUBLIC PERSPECTIVE  
Since there is growing   knowledge   that  healing   of  microalbuminuria  
in patients without glycemic impairment  will  have  a cost effective 
alternative to prevent cardiovascular disease, all health care 
professionals  should heed more need  to  the   early  diagnosis  and  further 
management  of  patients  with microalbuminuria. 
As of, now many antibody-tests are used to asses lower levels of both 
qualitative and qualitative urine albumin.  These include nephelometry, 
ELISA.  Immuno turbidimetry, RIA
38
.   
It has been said  the gold standard diagnostic method for 
microalbuminuria is the radio immunoassay; many other tests which are done 
in standard labs are generally highly sensitive for routine clinical usage. Immuno 
turbidimetric test for microalbuminuria has been based on the quantification 
liquid phase immunoprecipitation. Antibodies against human albumin are added 
to an aliquot  of patient urine and reaction buffer.  The antibodies 
undergo an agglutination reaction with albumin in urine, resulting in an 
increase in turbidity of the mixture. Turbidity is measured using a clinical 
chemistry analysis at a wavelength of Ca 405 nm. 
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MICROALBUMINURIA KIT SHOWING TEST STRIPS, AUTOANALYZER AND 
TESTING FOR MICROALBUMINURIA 
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In the recent past, a novel way was started with which both 
immunoreactive and immuno unreactive albumin. can be m e a s u r e d . 
Previously only one type could be assessed    with this type of test, large 
number of patients hitherto not overtly albuminuric were found to have 
protein excretion in microalbuminuric range
40
.  
But at present it is not known that the patients who have been screened 
by the novel method are having the same risk. But it is prudent to. measure 
albuminuria in fresh sample than old sample 
For a long time Because of the effort involved, even though not the 
method of choice for it has been accepted that gold standard test for micro 
albuminaria is 24 hr urine sample screening. But in practice this carries lot of 
difficulties. The next best option is timed urine collected overnight. This also 
runs into practical difficulties  because this demands  urine collection  over a 
given time, this may be  used for high risk screening specific groups such as 
patients with diabetes or hypertension, hitherto it is not practical  for general 
public  screening. Another option is first-morning urinary sample. This has 
the  certain good points compared to a spot-urine sample since  it mostly 
always done  at the same time of that particular day , and it not that much 
affected by patients  status and if patient engages in any physical activity, 
which will negate the variance influenced by the above two determinants
41
. 
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But in actual clinics, a spot-urinary sample is gathered when the 
subject sees the physician or at the primary health centre where the sample is 
collected. 
In order to quantify albuminuria, usually the elimination of 
albumin in unit time has to be assessed: UEA IN a 24 hour sample or it may 
be calculated per minute (as in regarding timed night samples). Regarding 
untimed collection, it’s better to assess the spot albumin : creatinine  proportion 
The introduction of albumin--creatinine proportion creates a different 
problem as it necessitates, use of varying. Terminologies for abnormal 
results for males and females Also, creatinine elimination are dependent not 
gender but age and race. So its better to do a urinary albumin assessment 
from a spot collection is equally good for the assessment of 
microalbuminuria in terms of albumin creatinine proportion
42
. 
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Table 5: Classification of abnormal urinary albumin 
excretion 
 
 
 
 
24 Urine 
Albumin 
(mg/24 h) 
 
 
Overnight 
Urine Albumin 
(microg/min) 
 
Spot Urine 
 
 
Albumin 
(mg/L) 
 
Alb/Creatinine proportion 
 
Gender 
 
mg/mmol 
 
mg/g 
 
 
Normal 
 
 
<15 
 
 
<10 
 
 
<10 
 
M 
 
<1.30 
 
<11 
 
female 
 
<1.77 
 
<16 
 
 
 
High limit 
 
 
 
16 to <30 
 
 
 
11 to <21 
 
 
 
11 to <21 
 
M 
 
1.25 to 
<2.5 
 
10 to 
<20 
 
F 
 
1.76 to 
<3.5 
 
15 to 
<29 
 
 
 
Micro albuminuria 
 
 
 
32 to 
<299 
 
 
 
22 to <100 
 
 
 
22 to 
<220 
 
M 
 
2.6 to 26 
 
20 to 
<200 
 
F 
 
3.6 to 36 
 
30 to 
<300 
 
 
Macroalbuminuria 
 
 
>300 
 
 
>200 
 
 
>200 
 
M 
 
>25 
 
>200 
 
F 
 
>35 
 
>300 
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Ideally if a patient is having positive microalbuminuria he should be 
repeatedly screened. Ideally test should be twice or thrice repeated. its taken 
as positive if best of three values is positive
43, 44 
 
It has been recently surmised that occurrence of micro albuminaria 
may precede the occurrence of overt glycemic impairment and systemic 
hypertension. Micro albuminaria has also been hypothesized as a warning 
sign for insulin resistance. It has also been shown that the quantitative 
excretion of microalbuminuria has a direct relationship as overt 
manifestation of metabolic syndrome X manifests. All this leads us to 
doubt whether micro albuminaria can be used a determination and 
screening tool for various non communicable diseases rather than 
treating it as an innocent bystander
45
. 
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METHODOLOGY 
 
 
 
Study Design 
 
Randomised hospital based study. 
 
Study subjects 
 
Fifty (50) non-diabetic subjects with Ischemic Heart Disease 
attending the outpatient clinic or admitted as inpatients in the Department of 
Medicine and cardiology wards,  
 
 Inclusion Criteria 
The diagnosis of Ischemic Heart Disease was based on the 12 lead 
ECG and exercise thread mill testing (in two subjects), cardiac enzyme 
estimation and the Rose questionnaire. Also echocardiogram was done to 
asses ejection fraction 
 
Exclusion Criteria 
 
1.  Diabetic patients by ADA criteria (2004). 
 
2.  Congestive cardiac failure as presentation. 
 
3.  Urine showing 
 
- Macro albuminuria (dipstick positive albuminuria) 
 
 
- RBCs > 50/µl 
 
 
- Leucocytes > 75/µl 
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4.  Female patients with vaginal discharge. 
 
 
 
Method of collection of data 
 
This was a hospital based retrospective study involving 50 patients. 
Data collection was by clinical history, examination and investigations. 
These details were recorded as per the proforma attached as annexure. 
The patients included in the study were first self reported, infarct 
pattern, major or minor ischemia by ECG or TMT positive for inducible 
ischemia. Cardiac enzyme estimation was done. Echo cardiography was 
employed to measure the ejection fraction. 
The patients were given a container for collection of urine over 24 
hours which was then sent for estimation of microalbuminuria level by 
immune turbidimetry method. The result was reported as x mg/day of 
albumin. 
Statistical Analysis 
 
 
The data is presented as Mean ± SD. The limit of significance was 
calculated using SPSS Version 15 software. 
 
Statistical Software 
Both MS word and excel of windows 7 ultimate were extensively 
utilized for drawing graphs, tables, etc.  Statistical software namely ANOVA 
& SPSS Version 16 was used for the analysis of data. 
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RESULTS 
 
 
 
 
Fifty (50) patients fulfilling the criteria for the study were included. 
The study was done over a period of one and half years. Data was collected 
as per the proforma attached. 
 
1) Sex distribution 
 
In the present study, out of 50 patients, 37 were males and 13 were females. 
 
 
 
Table 6: Sex distribution in study subjects 
 
 
 
Sex 
 
Number of 
patients 
 
Percentage 
 
Male 
 
37 
 
74 
 
Female 
 
13 
 
26 
 
  
 59 
 
P
ag
e5
9
 
 
 
 
 
 
 
 
 
 
Figure 5: Sex distribution in study subjects 
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37 (74% ) 
 
 
 
 
Male 
Female 
 
 
Male to female ratio was 2.85:1 in the study. 
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2) Age distribution in the study subjects 
 
Table 7: Age distribution in the study subjects 
 
 
 
Age 
Sex Total 
Male Female  
26-35 4 0 4 
36-45 4 0 4 
46-55 11 2 13 
56-65 12 9 21 
66-75 6 2 8 
Total 37 13 50 
 
 
The mean average age of the study group   was 55.68 ± 11.10 years.             
It was 54 ± 19 years for male and 59.92 ± 6.42 for females. Subject in the age 
group 56-65 constituted 42% of the study group. Majority of females were aged 
above 55 years (84.61%). 
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Figure 6: Age distribution in the study subjects 
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3) Family history of Ischemic Heart Disease 
 
 
Table 8: Family history of Ischemic Heart Disease 
 
 
 
 
Family history of  
IHD 
 
Sex 
 
Total 
 
Male (n=37) 
 
Female (n=13) 
 
 
No 
 
20 
 
10 
 
30 
 
Yes 
 
17 
 
3 
 
20 
 
 
A positive history of IHD   was present in 40% of the study subjects. 
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Figure 7: Family history of Ischemic Heart Disease 
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4) History of current smoking 
 
Table 9: Patients with history of smoking 
 
 
 
History of 
smoking 
 
Sex 
 
 
Total  
Male (n=37) 
 
Female (n=13) 
 
No 
 
1 
 
13 
 
14 
 
Yes 
 
36 
 
0 
 
36 
χ2  – 9.680; p<0.002 
  
 
There was no female patient with history of smoking whereas 97.3% 
of the male patients gave a history of smoking. 
Smoking history was present in 72% of the study subjects (P<0.002) 
which was statistically significant. 
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Figure 8: Patients with history of smoking 
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5) Body Mass Index 
 
Table 10: Distribution of BMI 
 
 
BMI (kg/m
2
) 
 
Males (n=37) 
 
Female (n=13) 
 
Total 
 
< 23 
 
0 
 
0 
 
0 
 
23-25 
 
7 (18.9%) 
 
1 (7.7%) 
 
8 (16.0%) 
 
> 25 
 
30 (81.1%) 
 
12 (92.3%) 
 
42 (84.0%) 
χ
2  
–23.12; p<0.00 
 
 
 
 
The mean  BMI  was  25.87±  0.96  in  males  and  27.76  ±  2.17  in  
females. Majority of the patients were obese (84%). Female patients had a 
higher incidence of obesity in the present study. 
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Figure 9: Distribution of BMI 
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6) Hypertension 
 
Table 11: Patients with Hypertension in the present study 
 
 
BP 
 
Sex 
 
 
Total (n=50) 
 
Male (n=37) 
 
Female (n=13) 
 
Normal 
 
18 (48.6%) 
 
3 (23.1%) 
 
21 
 
Hypertension 
 
19 (51.4%) 
 
10 (76.9%) 
 
29 
χ
2  
– 1.280; p<0.25 
 
 
 
 
Hypertension was present in 58% of the study subjects of which 
females had a higher percentage (Male to Female – 51.4% to 76.9%). The 
mean systolic BP was 144.81± 10.84 in males and 148± 8.97 in females. The 
mean diastolic BP was 88.86± 6.84 in males and 90.0 ± 8.16 in females. 
  
 69 
 
P
ag
e6
9
 
 
 
 
 
 
P
e
rc
e
n
ta
g
e
 o
f 
c
a
s
e
s
 
 
 
 
 
 
 
 
Figure 10: Patients with Hypertension in the present study 
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7) Blood Glucose values in the study group 
 
Table 12: Blood glucose values in the study group 
 
 
Blood Glucose (mg/dl) 
 
Males (n=37) 
 
Females (n=13) 
 
FBS 
 
100.05± 8.87 
 
100.00±8.25 
 
PPBS 
 
139.54±15.81 
 
135.23± 22.26 
 
 
The mean FBS was 100.04± 8.63 mg% and mean PPBS was 
 
 
138.42 ± 17.51 mg% in this study group. 
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Figure 11: Blood glucose values in the study group 
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8) Lipid profile in the study subjects (in mg/dL) 
 
Table 13: Lipid profile in the study subjects (in mg/dL) 
 
  
Males (n=37) 
 
Females (n=13) 
 
Serum total cholesterol 
 
176.54± 22.73 
 
190.84± 20.51 
 
Serum Triglycerides 
 
134± 25.37 
 
170.00±86.71 
 
Serum H.D.L 
 
42.59± 2.98 
 
41.92± 6.14 
 
LDL cholesterol 
 
122.00 ± 22 
 
124.92 ± 23.47 
 
 
The mean triglycerides mean total cholesterol and mean LDL – 
cholesterol was higher in females in this study. 
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Figure 12: Lipid profile in the study subjects (in mg/dL) 
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9) Abnormal lipid parameters 
 
Table 14: Abnormal lipid parameters 
 
 
Lipid parameters 
 
Males n=37 
 
Females n=13 
 
Total n=50 
 
Total cholesterol (>200 mg %) 
 
6 (16.2%) 
 
3 (23.1%) 
 
9 (18%) 
 
Triglycerides (>150 mg %) 
 
10 (27%) 
 
7 (53.8%) 
 
17 (34%) 
 
HDL (M<40 mg% F<50 mg %) 
 
4 (10.89%) 
 
11 (84.6%) 
 
15 (30%) 
 
LDL-C (>150 mg %) 
 
4 (10.8%) 
 
1 (7.7%) 
 
5 (10%) 
 
 
In this study the major dyslipidemia was hypertriglyceridemia (39%) and 
low HDL (30%) which is a typical Indian lipid profile pattern. 
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Figure 13: Abnormal lipid parameters 
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10) Microalbuminuria 
 
Table 15: Levels of microalbuminuria (mg/day) 
 
 Males Females Combined 
< 30 10 (27%) 2 (15.3%) 12 
30-50 16 (43.2%) 6 (46.29) 22 
> 50 11(29.8%) 5 (38.5%) 16 
χ
2
- 13.52; p<0.000 
 
 
There was   27   males ( 73%)   and   11   females ( 84.7%) w i t h  
a b n o r m a l  microalbuminuria levels in the present study. 
This shows tha t  s u b j e c t s  w h o  h a v e  o v e r t  mi c ro  albuminuria 
h ad  a  g r e a t e r  chance o f  developing ischemic heart disease (p<0.000) 
More female patients in the present study had abnormal 
microalbuminuria (84.7%) compared to male patients (73%). 
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Figure 14: Levels of microalbuminuria (mg/day) 
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11) Distribution of microalbuminuria in various age groups 
 
Table 16: Distribution of microalbuminuria in various age groups 
 
 
 
 
Age (years) 
 
Albuminuria (mg/day) 
 
<30 
 
≥ 30 
 
26-35 
 
1 (25%) 
 
3 (75%) 
 
36-45 
 
1(25%) 
 
3 (75%) 
 
46-55 
 
3 (23%) 
 
10 (77%) 
 
56-65 
 
6 (28.57%) 
 
15 (71.43%) 
 
66-75 
 
1 (12.5%) 
 
7 (87.5%) 
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12) Relation of Microalbuminuria with Ischemia /infarct pattern on ECG 
 
Table 17: Relation of Microalbuminuria with Ischemia /infarct pattern on ECG 
  
Microalbuminuria (mg/d) 
 
<30 
 
≥ 30 
 
Ischemia 
 
4(25%) 
 
12 (75%) 
 
Infarct 
 
8 (23.6%) 
 
26(76.4%) 
χ
2  
– 13.52; p<0.000 
 
 
The incidence of microalbuminuria increased with increasing age except in 56- 
65 age group in the present study. 
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Figure 15: Relation of Microalbuminuria with Ischemia /infarct pattern on ECG 
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13) Relation between Microalbuminuria hypertension and ischemia/infarct 
pattern 
 
Table 18: Relation between Microalbuminuria hypertension and ischemia/ 
infarct pattern 
 
Microalbuminuria 
(mg/day) 
 
 
BP 
 
 
Ischemia 
 
 
Infarct 
 
 
<30 
 
Normal 
 
Hypertension 
 
3 
 
1 
 
3 
 
5 
 
 
≥ 30 
 
Normal 
 
Hypertension 
 
3 
 
8 
 
12 
 
15 
 
 
Out of the 29 patients with hypertension, 23 patients had 
microalbuminuria i.e., 79% of hypertensive patients had abnormal 
microalbuminuria. Fifteen out of 21 normotensive patients also had 
microalbuminuria (71.4%).  
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Figure 16: Relation between Microalbuminuria hypertension and ischemia/ 
infarct pattern 
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14) Relation between smoking, Microalbuminuria and Ischemia / Infarct 
 
Table 19: Relation between smoking, Microalbuminuria and Ischemia / Infarct 
 
 
 
 
Smoking 
Microalbuminuria 
(mg/day) 
 
Ischemic 
 
Infarct 
Chi- 
square 
 
p-value 
 
No 
<30 
≥ 30 
0 
5 
3 
6 
 
2.12 
 
>0.05(NS) 
 
Yes 
< 30 
≥30 
4 
6 
5 
21 
 
1.66 
 
>0.05(NS) 
 
These were 36 patients with history of smoking out of which 27 
patients (75%) had microalbuminuria compared to 78% of non-
smokers with microalbuminuria. 
77.8% of smokers with microalbuminuria presented
 with myocardial infarction compared to 54.5% of non-smokers with 
microalbuminuria, who presented with myocardial infarction. 
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Figure 17: Relation between smoking, Microalbuminuria and Ischemia / Infarct 
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15) Relationship between total cholesterol microalbuminuria, ischemic/infarct 
 
Table 20: Relationship between total cholesterol microalbuminuria, Ischemic/ 
infarct 
Total 
cholesterol 
(mg/dl) 
 
Microalbuminuria 
(mg/day) 
 
 
Ischemia 
 
 
Infarct 
 
Chi- 
square 
 
 
p-value 
 
< 200 
<30 
≥ 30 
3 (23.1%) 
10 (76.9%) 
7 (25.0%) 
21 (75.0%) 
 
0.17 
 
>0.05(NS) 
 
≥ 200 
< 30 
≥ 30 
1 (50%) 
1 (50%) 
1 (14.3%) 
6 (85.7%) 
 
1.15 
 
>0.05(NS) 
 
  
Out of the patients  with abnormal total cholesterol ,  7             
(i.e.  77.7%)  had microalbuminuria  ≥  30  mg/day,  where  as  out  
of  the  41  patients  with  normal cholesterol 31 patients (75.6%) had 
microalbuminuria. 
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Figure 18: Relationship between total cholesterol microalbuminuria, Ischemic/ 
infarct 
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16) TROP T STATUS IN THE STUDY POPULATION 
 
Table 21:  Trop T status in the study subjects  
 
  
Males (n=40) 
 
Females (n=10) 
Trop T (+) 30 10 
Trop T (-) 7 3 
 
 
80% of the total patients were having Trop T positivity. 81% of males were having 
Trop T positivity as compared to 77% of the female with Trop T positivity 
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17) DISTRIBUTION OF EJECTION FRACTION AMONG STUDY POPULATION 
 
 
Table 22:  EJECTION FRACTION 
 
Ejection 
Fraction (%) <50 50-60 >60 
Male 18 13 6 
Female 3 6 4 
Total 21 19 10 
 
80% of the total patient had ejection fraction <60% of this 84% of the males 
had ejection fraction <60% as compared to 70% of females had ejection fraction 
<60%. 
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DISCUSSION 
 
 
 
Ischemic Heart Disease will become a major disease burden in India 
by the year 2018.   To target preventive strategies, risk stratification of the 
population should be effective. There are many reports emanating from the 
western literature about micro albuminuria where it is already considered in 
many countries as an independent risk determinant for development of 
ischemic heart disease
46
 
 
Hitherto,  microalbuminuria  was  considered  as  a  marker  of  
endothelial dysfunction in diabetes mellitus, but many studies have shown 
micro albuminuria has become an   effective  indicator of   generalised   
vascular  dysfunction  even  in  non-diabetic population.
47,48 
 
This study was done to find out whether there is an association between 
IHD and MA in non-diabetic subjects. 
 
In the present study, the diagnosis of IHD was by ECG changes. de 
Bruyne MC et al.  Have shown that ECG may be used as a screening tool for 
mass screening of IHD in general population.
49 
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This study had 74% male patients compared to 26% female patients. 
This is in accordance with the knowledge that males are more prone for 
ischemic heart disease than females.Also the EPIC NORFLOK study had 
higher male incidence which is in concordance with my study
41 
 
In my study the mean age of the study group   was 55.68 ± 11.10 years.  
It was 59.92 ± 6.42 years for females. All the females were in the post-
menopausal age group, which shows that sex hormones have a protective 
effect as far as cardiovascular risk is concerned This is  in concordance  with 
the fact that Roeste and Banga et al have  demonstrated that urinary albumin 
excretion in significantly higher in  non diabetic postmenopausal group when 
compared to pre menopausal group
50, 51 
 
In this study, habit  of smoking was there in  72% of the study 
subjects indicating that smoke abuse may be an important  risk factor for 
IHD. Umesh N Khot et al.had found a prevalence of 41.6% in males and 
29.5% in females in their study for smoking as a risk factor
51, 59 
The BMI was > 25kg/m2 in majority of the study group. This 
prevalence was much higher than that obtained by Singh R.B. et al.(11.0% 
in rural and 27.2% in urban). 58% of patients in the present study had 
hypertension (51.4% in males and76.9% in females). This is much higher 
 - 91 - 
 
than the prevalence found by Fabitz et al by STRONG HEART STUDY 
(38.4% in males and 55.9% in females) but shows a similar trend
58, 59
. 
34% of the patients had hypertriglyceridemia and/or 30% of patients 
had low HDL levels, which was similar to that obtained by Voss and 
Cullen et al by the PROCAM study ( 39.6% of females and 34.1% of males 
had abnormal lipid parameters).
56, 57 
The present study showed that 76% of the patients with ischemic heart 
disease had microalbuminuria which shows a positive association. The 
PREVEND trial has demonstrated that  that in a multivariate adjusted 
scenario  while taking in comparison established risk determinants, the 
prescence of microalbuminuria was by itself having an independent  
association  with pattern of infarct (7.2%) (OR-1.62), major type of ischemia 
(10.8%) (OR-1.43) and minor varieties of ischemia (15.3%) (OR-1.33).
54,55,56 
 The prevalence of Micro albuminuria was estimated in 15 % of  a 
cohort of people in the HOPE(HEART OUTCOMES AND PREVENTION 
AND EVALUATION survey which was done in the years between 1998 and 
2003
52, 5 3 , 5 4
  
This survey revealed that 20.6% of subjects with microalbuminuria 
were having a higher incidence of coronary artery disease, myocardial 
infarction and stroke when compared with 13.8% of those who did not have 
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microalbuminuria. 
 
With regard to   PREVEND  trial,  32.4%  of  ischemic  coronary   
disease  patients  were described here, 20.8% of subjects  with ischemic 
cardiac  disease were having   microalbuminuria as in comparison  with  76% 
in this study
55,56
. 
This was probably because, the present study had a cohort of IHD 
patients in whom micro albuminuria was estimated whereas the studies 
mentioned above was done on the general population. 
The present trial design indicate that microalbuminuria may be used as 
a supplementary  Cardiac  risk determinant even among non-diabetics and in 
future may supplant existing markers currently used to quantify ischemic heart 
disease.
57, 60. 
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SUMMARY 
 
In the present study, 
 
1. Male to female ratio was 2.85:1. 
2. Subjects in the age group 56-65 years constituted 42% of the study group. 
84.6% of the female patients were above 55 years of age.  
3. The youngest patient in the study was 26 years old. 
4. 40% of patients had a family history of Ischemic Heart Disease. 
5. 80% of the patients had Trop T positivity. 
6. 80% of the patients had ejection fraction <60%.  
7. 72% of the patients had history of smoking. All of them were males                
(p < 0.002). 77.8% of smokers with microalbuminuria presented with 
myocardial infarction compared to 54.5% of non-smokers with 
microalbuminuria. 
8.  84% of the patients had a BMI > 25 kg/m2   (obese) and 16% were 
overweight (BMI 23-25 kg/m2). 
9. 79%  of  hypertensive  patients  had  microalbuminuria  compared  to  
71%  of normotensive patients. 52% of patients had abnormal lipid profile 
hypertriglyceridemia was present in 34% and low HDL in 30% of the 
patients. 
10. 84% of the females had microalbuminuria ≥ 30 mg/day compared to 
73% of males in the present study. Microalbuminuria ≥ 30 mg/day was 
present in 75% patients with ischemia pattern on ECG and 76.4% of 
patients with infarct pattern on ECG and 76% of all cases of Ischemic 
Heart Disease patients (p < 0.0001). 
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CONCLUSION 
 
Of 50 non diabetic patients with IHD were studied, 38% had 
microalbuminuria. 
Micro albuminuria is thus positively associated with Ischemic Heart disease 
in non diabetic patients.  
 It may be regarded as an important additional risk factor for ischemic heart 
disease. 
Hence in future aggressive screening among general population, particularly 
in young age group may be a worthwhile public tool for cardiac risk stratification.  
and targeting preventive strategies. 
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LIMITATIONS OF ABOVE STUDY AND SUGGESTIONS 
 
1. 1.Only a small sample size is covered 
2. ECG changes are used to screen for CAHD. Resting  ECG detects only 
50%of ischemia 
3. It is an observational study 
4. Hence further studies are needed in this regard be microalbuminuria could 
be cemented as a marker of ischemic heart disease  
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PROFORMA 
 
CASE NO: 
 
A. PATIENT PARTICULARS: 
Name  
   Age 
   Sex  
   Occupation  
   OP/Number IP/Number  
1. Chest pain Location 
Duration 
Type 
                             Radiation 
                                 Aggravating and relieving factors 
 
Associated symptoms 
 
2. Palpitations  
                       
                       Onset    
                       Duration   
                        Type 
                             Aggravating or relieving factors 
 
x 
 
 
3. Syncope Onset 
                              Duration  
                             Aggravating factors 
                                   Associated symptoms (palpitations, seizures) 
 
4. Dyspnoea Onset 
Progression 
Duration 
Paroxysmal nocturnal dyspnea 
 
Aggravating and relieving factors 
 
5. Easy fatiguability 
 
B. OTHER PRESENTING COMPLAINTS  
 
 
 
 
C. PAST HISTORY  
- Ischemic Heart Disease’ 
- Congestive cardiac failure 
- Stroke  
- Treatment for hypertension/bronchial asthma/Diabetes mellitus  
 
xi 
 
D. FAMILY HISTORY  
- Diabetes mellitus  
- Ischemic Heart Disease 
- Stroke 
- Hypertension 
 
E. PERSONAL HISTORY  
Diet- Vegetarian /Mixed 
Smoking (cigarette/beedis )  - Yes/No 
Alcohol     - Yes/No 
MENSTRUAL HISTORY: 
If menopausal _______________ years after menopause  
 
F. EXAMINATION  
1. Height 
2. Weight 
3. BMI 
4. Pulse   
5. Blood pressure  
6. General Examination 
 
7. Cardiovascular system  
 
8. Other systems: a.      RS  
                             b.       GIT 
                            c.       CNS 
 
xii 
 
INVESTIGATIONS  
 
1. Routine investigations  
2. FBS, PPBS 
3. Blood urea. 
4. Serum creatinine  
5. Fasting lipid profile  
-TC 
-TG 
-HDI 
-LDL 
6. 24 hours urine micro albumin  
7. 12 lead ECG 
- Infarct pattern  
-Major ischemia  
- Minor ischemia  
7. Treadmill testing (where indicated) 
8. Cardiac enzyme estimation  
9. Echocardiography-EF % 
 
 
 
 
 
 
 
 
xiii 
 
 
KEY TO MASTER CHART 
BMI   Weight/height
2
 
DBP   Diastolic BP 
FBS   Fasting Serum glucose 
HDL   High density lipoproteins  
Ht   Height  
IHD   Ischemic heart disease 
LDL   Low density lipoproteins  
MA   Microalbuminuria 
PPBS   Postprandial blood sugar 
SBP   Systolic blood pressure  
Sl.No   Serial Number 
TC   Total Cholesterol 
TG   Triglycerides 
Wt   Weight.  
+                               Present 
-                            Not present 
 
 
 
 
14 
 
MASTER CHART 
SL.NO NAME IP/OP NO 
Age in 
years  
 Sex 
Family 
history of 
IHD 
smoking  HT WT BMI SBP DBP FBS PPBS TC TG HDL LDL MA INFARCT ISCHEMIA  TROP T 
Ejection 
Fraction (%) 
1 ilangovan 1406337 34 Male Yes yes 168 75 26.6 130 80 96 140 186 102 40 125 78 AMI   
+ 55 
2 chandravel 1383210 35 Male No yes 172 78 26.4 140 90 102 144 208 154 41 128 26 AMI   
+ 48 
3 mohd ismail 138542 70 Male No yes 16 64 25 160 90 82 110 249 179 40 185 140 AMI   
+ 52 
4 pavalingam 1378823 55 Male Yes yes 165 69 25.3 140 80 90 146 142 110 39 81 40  - Yes 
- 58 
5 dhanakodi 1392123 61 Female No no 154 60 25.3 150 90 112 181 217 100 48 149 37  - Yes 
+ 56 
6 mariyammal 1384076 58 Female No no 158 64 25.6 140 90 84 115 176 141 34 113 17 IWMI   
+ 46 
7 pankajam 1390730 75 Female No no 154 74 31.2 160 90 100 120 179 111 52 104 74 AMI   
+ 45 
8 rukmani 1389049 68 Female No no 15 68 30.2 150 80 99 112 240 170 41 184 47 - Yes 
- 47 
9 
thaiyalnaya
gi 
1388034 56 Female Yes no 156 58 23.8 150 80 98 120 190 441 30 130 38  - Yes 
+ 53 
10 vasantha 1409530 60 Female No no 15 60 26.7 140 80 90 114 185 192 46 100 35  - Yes 
+ 51 
11 
subramania
n 
1401342 31 Male Yes yes 168 74 26.2 130 80 80 110 161 119 40 97 34 AMI   
+ 54 
12 paulraj 1416472 53 Male Yes yes 172 74 25 140 80 88 112 156 116 40 92 40 AMI   
+ 44 
13 muthu 1402591 65 Male No yes 174 76 25.1 150 80 98 130 175 120 44 107 28 AMI   
+ 46 
14 vadivel 1396537 48 Male Yes yes 166 70 25.4 130 80 100 140 202 167 49 120 71 AMI   
+ 53 
15 anjammal 1408946 60 Female No no 15 68 30.2 130 90 104 150 175 146 45 102 59 AMI   
- 52 
xiv 
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16 kamaraj 145971 26 Male No yes 168 70 24.8 130 90 90 110 184 101 45 120 92 AMI   
+ 43 
17 rajendran 1386485 56 Male Yes yes 166 72 26.1 150 90 80 110 178 187 48 92 40  - Yes 
+ 41 
18 Sahayaraj 1398263 50 Male No yes 168 75 26.6 140 80 88 108 180 110 48 124 26 AMI   
+ 60 
19 lakshmi 1386728 54 Female Yes no 154 68 28.7 150 80 90 110 210 164 44 138 34 AMI   
- 55 
20 anbazhagan 1401284 58 Male Yes yes 174 80 26.4 150 90 100 138 188 114 40 138 80 IWMI   
+ 42 
21 apaviraja 1385186 66 Male No yes 17 74 25.6 160 80 99 150 154 114 42 98 39 AMI   
+ 43 
22 arokiyasami 1385648 62 Male Yes yes 168 72 25.5 140 80 102 140 160 120 40 120 40  - yes 
- 46 
23 
muthukrishn
an 
1388436 60 Male No yes 174 80 26.4 150 94 112 160 190 115 40 140 46  - Yes 
+ 48 
24 yasodhai 1389325 50 Female No no 145 60 28.5 148 100 104 140 170 100 45 120 39 IWMI Yes 
+ 51 
25 thambaiyan 1411487 69 Male No yes 166 65 23.6 150 90 114 150 180 110 44 154 70 AMI   
+ 54 
26 
dhanalaksh
mi 
1386776 57 Female No no 152 66 28.6 140 100 100 134 200 168 43 140 54  - Yes 
+ 56 
27 asokan 1394234 40 Male Yes yes 168 74 26.2 130 90 104 140 200 160 44 170 38  - Yes 
+ 47 
28 sreenivasan 1395355 49 Male No yes 166 71 25.8 140 90 108 150 180 110 42 130 39 AMI   
- 42 
29 shanthi 121860 56 Female No no 15 62 27.6 160 90 110 158 176 141 35 114 28 AMI   
+ 43 
30 
thirugnana
m 
146330 54 Male Yes yes 162 69 26.3 150 80 104 142 142 110 42 90 25  - Yes 
+ 45 
31 sahayaraj 1398263 50 Male No yes 165 70 25.7 140 90 98 135 144 120 40 94 44 AMI   
+ 51 
32 devaki 1405916 60 Female No no 154 62 26.1 160 100 100 148 178 154 38 120 53 AMI   
+ 54 
33 ramaiya 1378965 62 Male Yes yes 166 74 26.9 170 100 108 154 204 170 44 132 48 AMI   
+ 60 
xv 
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34 ramaswamy 1382663 71 Male No no 164 70 26 140 100 104 160 150 134 40 110 28 AMI   
+ 63 
35 muthaiyya 1378737 40 Male Yes yes 17 78 27 130 90 110 154 160 120 44 108 39 AMI   
- 62 
36 
muthukrishn
an 
10448 64 Male No yes 164 68 25.3 140 90 100 130 184 192 44 108 40 AMI   
+ 63 
37 uthirapathi 1389120 42 Male No yes 169 75 26.3 130 80 94 138 180 134 43 127 71 AMI   
+ 55 
38 
george 
jayapal 
1389050 48 Male No yes 166 74 26.9 140 90 98 144 210 165 42 170 29  - Yes 
+ 54 
39 neelavathy 11660 60 Female No no 15 64 28.4 150 100 109 156 185 192 44 110 53  - Yes 
+ 56 
40 ambujam 1378917 40 Male Yes yes 17 74 25.6 140 90 110 144 175 140 38 120 27 AMI   
+ 53 
41 kamaraj 1396537 54 Male No yes 162 68 25.9 160 100 101 146 180 153 40 130 45 IWMI   
- 46 
42 
govindasam
y 
1409132 54 Male Yes yes 158 60 24 150 90 107 140 210 174 43 134 40 AMI   
+ 48 
43 arumugam 1401310 60 Male No yes 164 67 24.9 140 90 103 154 178 110 50 110 24  - Yes 
+ 49 
44 
palanimanik
am 
1402363 65 Male No yes 168 69 24.5 144 94 94 130 154 140 43 136 38  AMI   
+ 52 
45 leninraj 1395392 70 Male Yes yes 158 62 24.8 150 100 99 142 160 120 42 110 54  - Yes 
+ 56 
46 ravindran 14033696 58 Male Yes yes 174 84 27.7 160 100 110 150 170 135 45 130 68 AMI   
- 58 
47 
krishnaswa
mi 
1405453 75 Male No yes 163 68 25.6 164 90 104 134 175 146 40 112 70  - Yes 
+ 62 
48 kunjupillai 1406259 60 Male No yes 167 74 26.5 150 90 105 158 164 130 39 134 25 AMI   
+ 47 
49 nagendran 1412021 60 Male No yes 157 68 27.6 140 90 110 170 150 124 46 108 30 AMI   
- 46 
50 
veniktachal
am 
1378973 58 Male Yes yes 174 84 27.7 160 100 110 150 170 134 45 130 68   Yes 
+ 55 
xvi 
xvii 
 
 
 
 
 
 
ACE 
 
ACR 
 
ARBs 
 
 
CAD 
 
CRP 
 
CVD 
 
EDRF 
 
 
 ELISA 
 
 
HDL 
 
IHD 
 
IL-1β 
 
LDL 
 
MA 
 
NO 
 
RIA 
 
TMT 
 
TNF 
 
UAE 
 
    VCAM-1 
LIST OF 
ABBREVIATIONS 
 
 
Angiotensin Converting 
Enzyme 

Albumin Creatinine Ratio 

Angiotensin Receptor 
Blockers 

Coronary Artery Disease 

C - reactive protein 

Cardio vascular disease 

Endothelium-derived 
releasing factor 

Enzyme Lined 
Immunosorbent Assay 

High Density Lipoprotein 

Ischemic Heart Disease 

Interleukin-1β 

Low Density Lipoprotein 

Microalbuminuria 

Nitric Oxide 

Radio immunoassay 

Thread Mill Testing 

Tumour necrosis factor 

Urinary albumin excretion 

Vascular cell adhesion 
molecule 
 
 
